Justification and selection of a hepatoprotective agent for the complex therapy of patients with psoriasis

Kokhan M.M., Filimonkova N.N., Kiseleva N.V., Gilyazova I.N.

Ural Research Institute of Dermatovenereology and Immunopathology, Yekaterinburg, Russia

Background: Psoriasis is a common chronic multifactorial, immune-mediated inflammatory skin disease, often associated with a high risk of developing comorbid cardiovascular diseases, metabolic syndrome, as well as liver pathology, including iatrogenic, ari-sing in the process of systemic therapy, which is reflected in a brief review of domestic and foreign publications.
Objective: Evaluation of the nature and severity of systemic inflammation indicators and the profile of changes in the blood serum lipid spectrum in patients with severe psoriasis, justification of the choice of a hepatoprotective agent with a pathogenetically justified complex effect.
Materials and methods: A clinical and laboratory examination of patients with severe psoriasis (PASI index over 20 points) with an assessment of hemogram indicators, biochemical hepatogram, including peripheral blood lipidogram, group and subgroup data analysis using the Statistica 10 program was conducted.
Results: In patients with severe clinical manifestations of psoriasis (in the absence of joint lesions), a pronounced proinflammatory reaction of the peripheral blood with an increase in the neutrophil/lymphocyte ratio in combination with a high serum CRP-ultra level was established. It was shown that the presence of immune-mediated inflammation in this cohort of patients with psoriasis was combined with high atherogenic lipidogram indices and reduced serum phospholipid levels, which are “predictors” of the formation of comorbid cardiovascular and liver pathology.
Conclusion: The results of the study confirm the need to include a hepatoprotector in the complex therapy of patients with psoriasis and justify the choice of a drug containing essential phospholipids and glycyrrhizic acid, which is determined by the pharmacological properties of this drug providing both a “replacement”, hepatoprotective, and anti-inflammatory effect in psoriasis and comorbid conditions.

Keywords

About the Authors

Muza Mikhailovna Kokhan, Dr. Sci. (Med.), Professor, Head of the Scientific Clinical Department of Dermatology, Ural Research Institute for Dermatovenereology and Immunopathology, Ekaterinburg, Russia; mkokhan@yandex.ru, ORCID: https://orcid.org/0000-0001-6353-6644 (corresponding author)
N.N. Filimonkova, Dr. Sci. (Med.), Professor, Leading Researcher of the Scientific Clinical Department of Dermatology, Ural Research Institute for Dermatovenereology and Immunopathology, Ekaterinburg, Russia; nnfil2008@mail.ru, ORCID: https://orcid.org/0000-0003-2872-3836
N.V. Kiseleva, Researcher, Experimental Laboratory Department, Ural Research Institute for Dermatovenereology and Immunopathology, Ekaterinburg, Russia; enkisa@rambler.ru, ORCID: https://orcid.org/0000-0002-2609-7977
I.N. Gilyazova, Junior Researcher, Scientific Clinical Department of Dermatology, Ural Research Institute for Dermatovenereology and Immunopathology, Ekaterinburg, Russia; inna.gilyazova@list.ru, ORCID: https://orcid.org/0009-0003-7781-6147

Similar Articles